Illustration: Lindsey Bailey/Axios
HexemBio raised $10.4 million in seed funding led by Draper Associates, CEO Gabriel Levesque Tremblay tells Axios Pro exclusively.
Why it matters: The startup is tackling a foundational problem in aging: the decline of blood stem cells that underpin the immune system.